Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects

Clinica Chimica Acta

Volumn 411, Issue 9-10, 2010, Pages 675-678

  Huang, Wenbao ^a   Zhu, Guoxian ^b   Huang, Meixian ^a   Lou, Guoqiang ^b   Liu, Yi ^a   Wang, Shuying ^a  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b The Sixth People's Hospital of Hangzhou   (China)

Author keywords

Hepatic fibrosis; Hepatic inflammation; Hepatitis C virus; Osteopontin

Indexed keywords

OSTEOPONTIN;

ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

AREA UNDER CURVE; BIOLOGICAL MARKERS; FEMALE; HEPATITIS C; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; MALE; OSTEOPONTIN; ROC CURVE; SENSITIVITY AND SPECIFICITY;

HEPATITIS C VIRUS;

EID: 77950460585     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.01.029     Document Type: Article

References (44)

1. Stanta G., Croce L.S., Bonin S., Tisminetzky S.G., Baralle F.E., Tiribelli C. Cohort effect of HCV infection in liver cirrhosis assessed by a 25year study. J Clin Virol 2000, 17:51-56.
2. Testino G. Hepatocarcinoma in HCV compensated correlated liver cirrhosis: role of treatment with interferon. Recent Prog Med 2002, 93:302-307.
3. Papatheodoridis G.V., Davies S., Dhillon A.P., et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplant 2001, 72:412-418.
4. Espinosa M., Martin-Malo A., Alvarez de Lara M.A., Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001, 16:1669-1674.
5. Pasta L., Marrone C., D'Amico M., Bevacqua E.A., D'Amico G., Pagliaro L. Familial clustering of HCV-related liver cirrhosis and hepatocellular carcinoma. Dig Liver Dis 2005, 37:716-717.
6. Sola R., Alvarez M.A., Balleste B., et al. Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients. Liver Int 2006, 26:62-72.
7. Osada S., Kanematsu M., Imai H., Goshima S., Sugiyama Y. Hepatic fibrosis influences the growth of hepatocellular carcinoma. Hepato-gastroenterol 2008, 55:184-187.
8. Jaskiewicz K., Banach L., Lancaster E. Hepatic siderosis, fibrosis and cirrhosis: the association with hepatocellular carcinoma in high-risk population. Anticancer res 1997, 17:3897-3899.
9. Blenkinsopp W.K., Haffenden G.P. Aetiology of cirrhosis, hepatic fibrosis, and hepatocellular carcinoma. J Clin Pathol 1977, 30:579-584.
10. Sodek J., Ganss B., McKee M.D. Osteopontin. Crit Rev Oral Biol Med 2000, 11:279-303.
11. Giachelli C.M., Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000, 19:615-622.
12. Chabas D. Osteopontin, a multi-faceted molecule. Med Sci 2005, 21:832-838.
13. McKee M.D., Nanci A., Khan S.R. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 1995, 10:1913-1929.
14. Suzuki H., Amizuka N., Oda K., et al. Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in klotho-deficient mice. Arch Histol Cytol 2005, 68:371-381.
15. Sun J, Zhou H.J., Xu H.M., et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 2009.
16. Xie H., Song J., Du R., et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis 2007, 39:167-172.
17. Zhao L., Li T., Wang Y., et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 2008, 62:1056-1062.
18. Brunt E.M. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000, 31:241-246.
19. Montazeri G., Estakhri A., Mohamadnejad M., et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005, 5:32.
20. Cao W., Liu Y.J. Opn: key regulator of pDC interferon production. Nat Immunol 2006, 7:441-443.
21. Marra F., Arrighi M.C., Fazi M., et al. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 1999, 30:951-958.
22. Sato M., Suzuki S., Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003, 28:105-112.
23. Cheng K., Mahato R.I. Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst 2007, 24:93-146.
24. Lee S.H., Seo G.S., Park Y.N., Yoo T.M., Sohn D.H. Effects and regulation of osteopontin in rat hepatic stellate cells. Biochem Pharmacol 2004, 68:2367-2378.
25. Maeno Y., Nakazawa S., Dao le D., et al. Osteopontin is involved in Th1-mediated immunity against Plasmodium falciparum infection in a holoendemic malaria region in Vietnam. Acta tropica 2006, 98:305-310.
26. Sato T., Nakai T., Tamura N., et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 2005, 54:1254-1262.
27. Cantor H., Shinohara M.L. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat Rev 2009, 9:137-141.
28. Lieber A., He C.Y., Meuse L., et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997, 71:8798-8807.
29. Fox E.S., Cantrell C.H., Leingang K.A. Inhibition of the Kupffer cell inflammatory response by acute ethanol: NF-kappa B activation and subsequent cytokine production. Biochem Biophys Res Commun 1996, 225:134-140.
30. Ramaiah S.K., Rittling S. Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury. Expert Opin Drug Metab Toxicol 2007, 3:519-526.
31. Apte U.M., Banerjee A., McRee R., Wellberg E., Ramaiah S.K. Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis. Toxicol Appl Pharmacol 2005, 207:25-38.
32. Banerjee A., Lee J.H., Ramaiah S.K. Interaction of osteopontin with neutrophil alpha(4)beta(1) and alpha(9)beta(1) integrins in a rodent model of alcoholic liver disease. Toxicol Appl Pharmacol 2008, 233:238-246.
33. Banerjee A., Apte U.M., Smith R., Ramaiah S.K. Higher neutrophil infiltration mediated by osteopontin is a likely contributing factor to the increased susceptibility of females to alcoholic liver disease. J Pathol 2006, 208:473-485.
34. Banerjee A., Burghardt R.C., Johnson G.A., White F.J., Ramaiah S.K. The temporal expression of osteopontin (SPP-1) in the rodent model of alcoholic steatohepatitis: a potential biomarker. Toxicol Pathol 2006, 34:373-384.
35. Banerjee A., Rose R., Johnson G.A., Burghardt R.C., Ramaiah S.K. The influence of estrogen on hepatobiliary osteopontin (SPP1) expression in a female rodent model of alcoholic steatohepatitis. Toxicol Pathol 2009, 37:492-501.
36. Koguchi Y., Kawakami K., Uezu K., et al. High plasma osteopontin level and its relationship with interleukin-12-mediated type 1T helper cell response in tuberculosis. Am J Respir Crit Care Med 2003, 167:1355-1359.
37. Konno S., Eckman J.A., Plunkett B., et al. Interleukin-10 and Th2 cytokines differentially regulate osteopontin expression in human monocytes and dendritic cells. J Interferon Cytokine Res 2006, 26:562-567.
38. Inomata S., Shijubo N., Kon S., et al. Circulating interleukin-18 and osteopontin are useful to evaluate disease activity in patients with tuberculosis. Cytokine 2005, 30:203-211.
39. Kwon H.J., Won Y.S., Yoon W.K., Nam K.H., Kim D.Y., Kim H.C. The role of osteopontin in d-galactosamine-induced liver injury in genetically obese mice. Toxicol Appl Pharmacol 2009.
40. Heilmann K., Hoffmann U., Witte E., et al. Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med 2008, Jul 4 [Electronic publication ahead of print].
41. Patani N., Jouhra F., Jiang W., Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008, 28:4105-4110.
42. Chang Y.S., Kim H.J., Chang J., Ahn C.M., Kim S.K., Kim S.K. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007, 57:373-380.
43. Musial K., Fornalczyk K., Zwolinska D. Osteopontin (OPN), PDGF-BB (platelet-derived growth factor) and BMP-7 (bone morphogenetic protein) as markers of atherogenesis in children with chronic kidney disease (CKD) treated conservatively-preliminary results. Pol Merkur Lekarski 2008, 24(Suppl 4):25-27.
44. Cho H., Hong S.W., Oh Y.J., et al. Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 2008, 134:909-917.